As medical and surgical methods for glaucoma treatment continue to expand, non-traditional and holistic therapies are worth being familiar with as they affect patients from all walks of life. Not all therapeutic modalitoes are created equal, and it is important to inderstand the science and efficacy of each.
As stated in a previous editorial, I plan to delve a little deeper into what we know about the family of glaucomas besides the gross oversimplification of “lower intraocular pressure means less progression.”
While that equation has certainly been proven true by a host of landmark longitudinal studies, let’s turn our attention briefly toward a couple of concepts other than our conventional intraocular pressure (IOP)-lowering medications and procedures about which we hear.
Among a commonly overlooked slew of potentially IOP-lowering molecules to which our patients are exposed are those found in products which fall under the category of complementary and alternative medicine.
We have all seen the labels which explicitly point out that the Food & Drug Administration (FDA) has not evaluated claims made by the makers of many of these products, but that doesn’t mean we should look past this slew of products.
One reason such products deserve our attention is the fact that patients are widely exposed to them through advertising. Further, it is wrong to assume that complementary and alternative medicine is available only to affluent people who can afford to shop at boutique health food stores.
Related: Glaucoma facts: Essential perspectives for long-term management
1. Chew EY, Clemons TE, SanGiovanni JP, Danis R, Ferris FL 3rd, Elman M, Antoszyk A, Ruby A, Orth D, Bressler S, Fish G, Hubbard B, Klein M, Chandra S, Blodi B, Domalpally A, Friberg T, Wong W, Rosenfeld P, Agron E, Toth C, Bernstein P, Sperduto R. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013 May 15;309(19):2005-15.
2. Steigerwalt RD Jr, Belcaro G, Morazzoni P, Bombardelli E, Burki C, Schönlau F. Mirtogenol potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects. Clin Ophthalmol. 2010 May 14;4:471-6.
3. Steigerwalt RD, Gianni B, Paolo M, Bombardelli E, Burki C, Schönlau F. Effects of Mirtogenol on ocular blood flow and intraocular hypertension in asymptomatic subjects. Mol Vis. 2008 Jul 10;14:1288-92.
4. Werner AC, Shen LQ. A Review of OCT Angiography in Glaucoma. Semin Ophthalmol. 2019;34(4):279-286.